For example, although most patients with echinoderm microtubule-associated protein-like 4 (EML4)-ALK positive non-small cell lung cancer (NSCLC) derive advantages from treatment with ALK inhibitors, the clinical response to these drugs varies significantly among such individuals9. This evidence concerns the gene ALK and non-small cell lung carcinoma.